<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136409</url>
  </required_header>
  <id_info>
    <org_study_id>01-214</org_study_id>
    <nct_id>NCT00136409</nct_id>
  </id_info>
  <brief_title>A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)</brief_title>
  <official_title>A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects (good and bad) of Gleevec in patients&#xD;
      with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid&#xD;
      metaplasia and chronic myelomonocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gleevec will be administered at a dose of 400 mg orally once daily.&#xD;
&#xD;
      Patients will continue to receive the drug until either drug progression or the development&#xD;
      of intolerable side effects.&#xD;
&#xD;
      Patients will be assessed with a complete blood count weekly for the first 8 weeks and will&#xD;
      have monthly physical examinations and bone marrow examinations every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the overall response rate of Gleevec as a single agent in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and efficacy of Gleevec as a single agent in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the biologic activity of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Myeloid Metaplasia</condition>
  <condition>Agnogenic Myeloid Metaplasia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Mono-Therapy Gleevec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gleevec administered orally at a pre-determined dose once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate</intervention_name>
    <description>400mg orally once daily until disease progression or unacceptable side effects</description>
    <arm_group_label>Mono-Therapy Gleevec</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a clinical diagnosis of myelofibrosis with myeloid metaplasia or&#xD;
             chronic myelomonocytic leukemia (CMML). Patients may be entered based on a prior&#xD;
             cytogenetic karyotype showing the absence of the Philadelphia chromosome.&#xD;
&#xD;
          -  Patients may be entered prior to completion of reverse transcription-polymerase chain&#xD;
             reaction (RT-PCR) or fluorescent in situ hybridization (FISH) studies, but a patient&#xD;
             who is subsequently found to be BCR-ABL or FISH positive will be removed from protocol&#xD;
             treatment. FISH will only be performed on patients with a normal karyotype. A PCR&#xD;
             sample will be sent on all patients.&#xD;
&#xD;
          -  The patients with myelodysplasia must have French-American-British (FAB) subtype&#xD;
             chronic myelomonocytic leukemia (CMML) defined as peripheral blood monocytosis, and&#xD;
             less than 30 percent blasts in the peripheral blood or the bone marrow.&#xD;
&#xD;
          -  The patients with myelofibrosis with myeloid metaplasia can have one of the following:&#xD;
             agnogenic myeloid metaplasia (idiopathic myelofibrosis), or post-polycythemic myeloid&#xD;
             metaplasia (post-polycythemic myelofibrosis), or post-thrombocythemic myeloid&#xD;
             metaplasia.&#xD;
&#xD;
          -  Estimated life expectancy of 6 months or greater.&#xD;
&#xD;
          -  Serum bilirubin equal to or less than twice the upper limit of normal.&#xD;
&#xD;
          -  Serum SGOT and SGPT equal to or less than twice the upper limit of normal.&#xD;
&#xD;
          -  Serum creatinine equal to or less than twice the upper limit of normal.&#xD;
&#xD;
          -  Age at least 18 years.&#xD;
&#xD;
          -  Greater than 4 weeks from any chemotherapy (except hydroxyurea), radiotherapy,&#xD;
             immunotherapy, or systemic glucocorticoid therapy (non-glucocorticoid hormonal therapy&#xD;
             is allowed). Systemic glucocorticoid therapy for non-malignant disease is allowed.&#xD;
&#xD;
          -  The last dose of hydroxyurea must be 24 hours prior to the initiation of Gleevec.&#xD;
&#xD;
          -  Greater than 2 months following bone marrow or peripheral blood stem cell&#xD;
             transplantation or treatment with donor lymphocyte infusion (DLI).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Pregnancy or nursing mothers.&#xD;
&#xD;
          -  Patients with myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia&#xD;
             who have transformed to acute myelogenous leukemia.&#xD;
&#xD;
          -  Prior treatment or diagnosis of acute myelogenous leukemia.&#xD;
&#xD;
          -  Patients with Philadelphia positive cytogenetics by either peripheral blood or bone&#xD;
             marrow sampling.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 3.&#xD;
&#xD;
          -  Prior exposure to Gleevec.&#xD;
&#xD;
          -  Active central nervous system (CNS) disease.&#xD;
&#xD;
          -  Evidence of infection with the human immunodeficiency virus.&#xD;
&#xD;
          -  Active psychiatric or mental illness making informed consent or careful clinical&#xD;
             follow-up unlikely.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. DeAngelo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Daniel J. DeAngelo, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>myelofibrosis</keyword>
  <keyword>agnogenic myeloid metaplasia with myelofibrosis</keyword>
  <keyword>CMML</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>imatinib mesylate</keyword>
  <keyword>Gleevec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

